Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Cogent Biosciences (COGT) Gains from Sales and Divestitures (2020 - 2025)

Cogent Biosciences' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $80000.0 for Q4 2025.

Quarterly Gains from Sales and Divestitures changed N/A to $80000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $80000.0 for FY2025, N/A changed from the prior year.
Gains from Sales and Divestitures came in at $80000.0 for Q4 2025, roughly flat from $80400.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $80000.0 in Q4 2025 to a low of $80000.0 in Q4 2025.